Document Detail


Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study.
MedLine Citation:
PMID:  10189007     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Oral propafenone is effective in restoring sinus rhythm however the proarrhythmic effects are still unknown. The Safety Antiarrhythmic Therapy Evaluation (SATE) trial was a prospective randomized placebo-controlled multicentre study which evaluated the safety of acute oral loading dose of propafenone in patients with recent onset atrial fibrillation. Secondary end-points were to evaluate the effect of digitalis added to propafenone in ventricular rate control and the efficacy of propafenone alone or added to digitalis compared with efficacy of digitalis plus quinidine. METHODS AND RESULTS: 246 patients (126 male; 58+/-11 years) with atrial fibrillation of <48 h duration were randomly allocated to one of four groups: digitalis 0.75-1 mg i.v. plus quinidine 1100 mg (D+Q, 70 patients); propafenone 450-600 mg orally (PNF, 66 patients); propafenone 450-600 mg orally plus digitalis 0.750-1 mg i.v. (PNF+D, 70 patients); placebo (Pl, 40 patients). All patients underwent 24-h ECG Holter monitoring. Safety was assessed by evaluating the appearance of adverse events classified as mild, moderate and severe. No severe adverse events were reported. Short lasting asymptomatic atrial flutter episodes with atrio-ventricular conduction > or =2:1 were observed in 14% of the D+Q group, 21% PNF, 18% PNF+D and in 8% Pl. One patient in the D+Q group and four in the PNF+D group showed asymptomatic runs of 3-4 ventricular ectopic beats. Reversible sinus atrial blocks (<3 s) were detected in two patients of the D+Q group and in two of the PNF group. In patients with persistent atrial fibrillation the ventricular rate was similar in the four study groups. At 3 h the high efficacy of propafenone was confirmed. At the 24th hour no differences were found between active treatment and placebo arms. CONCLUSION: Propafenone in a single oral loading dose is safe and promptly effective in patients with recent onset atrial fibrillation.
Authors:
A Capucci; G Q Villani; D Aschieri; M Piepoli
Related Documents :
7850817 - Probability of supraventricular tachycardia recurrence in pediatric patients.
1721147 - Effect of antiarrhythmic drug therapy on the incidence of shocks in patients who receiv...
2058557 - Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricul...
19996947 - Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation ...
19684847 - Improved glycaemic control with biphasic insulin aspart 30 in type 2 diabetes patients ...
19361027 - Platelet hyperreactivity in response to on- and off-pump coronary artery bypass grafting.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  International journal of cardiology     Volume:  68     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  1999 Feb 
Date Detail:
Created Date:  1999-05-21     Completed Date:  1999-05-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  187-96     Citation Subset:  IM    
Affiliation:
Department of Cardiology, General Hospital, Piacenza, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anti-Arrhythmia Agents / administration & dosage,  therapeutic use*
Atrial Fibrillation / drug therapy*,  physiopathology
Digitalis Glycosides / administration & dosage,  therapeutic use
Drug Therapy, Combination
Electrocardiography, Ambulatory
Female
Follow-Up Studies
Heart Rate / drug effects*
Humans
Male
Middle Aged
Propafenone / administration & dosage,  therapeutic use*
Prospective Studies
Quinidine / administration & dosage,  therapeutic use
Safety
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Digitalis Glycosides; 54063-53-5/Propafenone; 56-54-2/Quinidine
Comments/Corrections
Erratum In:
Int J Cardiol 1999 Jul 31;70(2):213

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogen...
Next Document:  Diagnostic and surgical trends, and epidemiology of coarctation of the aorta in a population-based s...